Triple Immunotherapy Combos Enter The Ovarian Cancer Fight
Executive Summary
Immunovaccine’s investigational cancer vaccine combined with an immunomodulator and a checkpoint inhibitor or other similar type of agent could have a synergistic beneficial effect on tumor cells, and lead to triple-drug combinations being evaluated in other cancers.
You may also be interested in...
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
CEO John Milligan offered few details about Gilead's deal strategy during an investor conference last week, but analysts think internal pressure for a major deal is beginning to equal the external sentiment, including an analyst who sees Incyte as a likely target, but not a quick fix for Gilead's declining HCV drug sales.
Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
In its second cancer deal in two months, Incyte licenses a first-in-class asset expected to offer potential cancer immunotherapy synergy with IDO1 and checkpoint inhibition.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.